Aurobindo Pharma reported its Q2 FY25 results, showcasing a steady year-on-year (YoY) growth. The company’s total revenue from operations reached ₹7,796.07 crore, marking an 8.9% increase compared to ₹7,219.44 crore in the same quarter last year. Sequentially, the revenue rose from ₹7,567.02 crore in the previous quarter, reflecting a quarter-on-quarter (QoQ) growth of 3%.
The profit for the period stood at ₹816.95 crore, up 8.6% YoY from ₹751.94 crore in Q2 FY24. However, on a QoQ basis, profit slightly declined from ₹918.22 crore in Q1 FY25, showing a decrease of 11.1%.
Key financial highlights:
Total Revenue from Operations: ₹7,796.07 crore, up 8.9% YoY from ₹7,219.44 crore and up 3% QoQ from ₹7,567.02 crore in the previous quarter.
Profit for the Period: ₹816.95 crore, reflecting an 8.6% increase YoY from ₹751.94 crore. On a QoQ basis, there was a decrease of 11.1% from ₹918.22 crore in Q1 FY25.
Key Highlights:
- US Formulations: Revenue grew by 4.3% YoY to ₹3,530 crore (USD 421 million), making up 45.3% of total revenue.
- Europe Formulations: Strong performance with a 19% YoY increase to ₹2,105 crore (EUR 229 million).
- Growth Markets: Significant YoY growth of 44%, reaching ₹812 crore (USD 97 million).
- ARV Segment: Declined by 22.8% YoY to ₹193 crore, impacted by changing market conditions.
- API Segment: Revenue was stable YoY at ₹1,156 crore.
Profitability Metrics:
- EBITDA before R&D costs stood at ₹1,954 crore, with a margin of 25.1%, showing a YoY increase from 23.3%.
- R&D Expenditure: Totaled ₹410 crore, representing 5.3% of revenue, supporting ongoing product innovation.
Operational Developments: Aurobindo Pharma received final approvals for 8 Abbreviated New Drug Applications (ANDAs) from the USFDA and launched 14 products in the quarter. The company filed 10 ANDAs and achieved a cumulative total of 848 ANDA filings, with 676 final approvals to date.
Management’s Remarks: Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, commented on the positive results, highlighting the resilience of Aurobindo’s diversified portfolio and strong revenue growth across key segments. Despite some pressure on profitability due to temporary factors, the company remains committed to its strategic goals and is confident in sustaining its growth momentum.
Aurobindo Pharma’s revenue growth was supported by steady performance across its segments, while the YoY profit increase highlights improved operational efficiencies. However, the QoQ dip in profit indicates potential challenges or higher costs faced during the quarter.
This financial performance demonstrates Aurobindo Pharma’s resilience in a competitive market, with a strong revenue growth trajectory.
